<DOC>
	<DOC>NCT00566982</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.</brief_summary>
	<brief_title>A Clinical Study to Evaluate the Safety of Ospemifene</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Naturally or surgically menopausal Intact uterus Vaginal pH greater than 5.0 5% or fewer superficial cells in maturation index of vaginal smear Evidence of endometrial hyperplasia, cancer or other pathology Abnormal Pap smear Uterine bleeding of unknown origin or uterine polyps Current vaginal infection requiring medication Use of hormonal medications Clinically significant abnormal gynecological findings other than signs of vaginal atrophy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Urogenital atrophy</keyword>
	<keyword>Menopausal symptoms</keyword>
	<keyword>Vulvar and vaginal atrophy in postmenopausal women</keyword>
	<keyword>Vaginal atrophy</keyword>
</DOC>